Exploring the FDA’s Flexibility With Novel Orphan Therapies, Neurological Rare Disease Special Report, Supplement to Neurology ReviewsFebruary 1, 2015 Download PDF
An interview with Frank Sasinowski was published in a Neurological Rare Disease Special Report, a Supplement to Neurology Reviews. In the interview, Mr. Sasinowski discusses how FDA has consistently exercised reasonable, appropriate, science-based flexibility in its review and approval of rare disease therapies.
If you have any questions regarding the above information, please contact:
Frank J. Sasinowski (202) 737-4287 email@example.com